Teva Pharmaceutical Industries Ltd (TEVJF) Liabilities and Shareholders Equity (2009 - 2026)

Teva Pharmaceutical Industries (TEVJF) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $39.9 billion in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 0.68% year-over-year to $39.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $160.5 billion (up 0.55% YoY) and the FY2025 annual result came in at $40.7 billion, up 3.62% from the prior year.
• Liabilities and Shareholders Equity held at $39.9 billion in Q2 2026, from $40.0 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $47.1 billion in Q1 2022 to a low of $38.4 billion in Q1 2025.
• A 5-year average of $42.1 billion and a median of $41.9 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity fell 10.19% — and 2026, when it climbed 4.23%.
• Tracing TEVJF's Liabilities and Shareholders Equity over 5 years: stood at $44.0 billion in 2022, then fell by 1.21% to $43.5 billion in 2023, then fell by 9.55% to $39.3 billion in 2024, then increased by 3.62% to $40.7 billion in 2025, then decreased by 2.19% to $39.9 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $39.9 billion (Q2 2026), $40.0 billion (Q1 2026), and $40.7 billion (Q4 2025), per Business Quant data.